226954-04-7
226954-04-7 结构式
基本信息
EMAPUNIL游离态
N-乙基-7,8-二氢-7-甲基-8-氧代-2-苯基-N-(苯基甲基)-9H-嘌呤-9-乙酰胺
N-苄基-N-乙基-2-(7-甲基-8-氧代-2-苯基-7,8-二氢-9H-嘌呤-9-基)乙酰胺
AC-5216
XBD-173
EMapunil
Emapunil(AC-5216)
AC 5216 (Emapunil)
XBD173 >=98% (HPLC)
AC-5216
XBD-173
EMAPUNIL
AC5216
AC 5216
N-Benzyl-N-ethyl-2-(7-Methyl-8-oxo-2-phenyl-7,8-dihydro-9H-purin-9-yl)acetaMide
N-Ethyl-7,8-dihydro-7-methyl-8-oxo-2-phenyl-N-(phenylmethyl)-9H-purine-9-acetamide
常见问题列表
| Target | Value |
|
mMBR(Brain)
(Cell-free assay) | 0.297 nM(Ki) |
|
MBR
(human glioma cells-based assay) | 2.73 nM |
|
MBR
(rat glioma cells-based assay) | 3.04 nM |
Emapunil (AC-5216, 0.1-3, 0.003-0.01 and 0.01-0.3 mg/kg, p.o.) produces anti-anxiety effects in the Vogel-type conflict test in rats, and in the light/dark box and social interaction tests in mice.
Emapunil (AC-5216, 3-30 mg/kg, p.o.) reduces the immobility time, and this effect was blocked by PK11195.
Emapunil (AC-5216, 1-100 mg/kg, p.o.) produces no distinct change in the rat electroencephalogram.
Emapunil (AC-5216, 0.3 and 1 mg/kg, i.g.) causes significant suppression of the enhanced anxiety and contextual fear induced in post-TDS rats.
Emapunil (AC-5216, 0.3 and 1 mg/kg, i.g.) alleviates the enhanced anxiety and fear response in a time-dependent sensitization (TDS) procedure, a rat PTSD animal model.
Emapunil (AC-5216, 0.3 and 1 mg/kg, i.g.) reverses the increased plasma glucose (PG) and decreased insulin (INS) in HFD-STZ rats.
| Animal Model: | Rats. |
| Dosage: | 0.1-3 mg/kg. |
| Administration: | P.O.. |
| Result: |
Significantly increased the number of shocks that rats received.
Significantly increased the time spent in the light compartment but only slightly increased that time at 0.03 mg/kg, p.o. (P<0.1). |